Enzymatica AB Reports Promising Q2 Growth in Sweden and Expanding Global Activities

Enzymatica AB: Results of Q2 2025

Enzymatica AB has recently released its quarterly report for the second quarter of 2025, highlighting considerable growth in Sweden along with an increase in international operations. According to the report, the company achieved net sales of SEK 8.3 million, up from SEK 6.4 million in the previous year. However, the operating result recorded a loss of SEK 14.9 million compared to a loss of SEK 13.5 million the prior year. Earnings per share also saw a change, landing at SEK -0.06 from SEK -0.08.

Comprehensive Overview

For the period from January to June, total net sales reached SEK 20.6 million, a rise from SEK 15.8 million for the same interval the previous year. Operating losses totaled SEK 32.9 million this half-year, compared to SEK 31.9 million a year earlier. The earnings per share during this time came out to SEK -0.13 compared to SEK -0.19 in 2024. Cash flows from operating activities showed similar declines, with a recorded flow of SEK -21.3 million versus SEK -19.0 million year-over-year.

CEO Claus Egstrand's Insights

Commenting on the results, CEO Claus Egstrand emphasized the company’s increased efforts in establishing new partnerships. “ColdZyme’s compelling clinical evidence is sparking significant global interest,” said Egstrand. He acknowledged the complexity involved in securing appealing deals, stressing the importance of patience and precision in identifying suitable commercial partners, especially within the EU, and already engaging discussions with global leaders in the over-the-counter treatment market.

Significant Developments in Q2

A notable event during the quarter was the announcement that Claus Egstrand would step down as CEO and be nominated for a position on the Board of Directors. This transition comes on the heels of the company’s strategic pivot toward international markets. Notably, partnerships in the UK with organizations like the United Kingdom Sports Institute (UKSI) and Aquatics GB have started yielding results, particularly in preparing athletes for the upcoming 2028 Olympic Games in Los Angeles.

The collaboration with UKSI aims to reduce the influence of colds on athletes’ training schedules by shortening illness durations, thereby helping maintain optimal performance. Additionally, ColdZyme was recently introduced to the UK winter Olympic team during a meeting in Edinburgh held in June.

In addition, the company has begun a marketing campaign featuring ColdZyme in collaboration with several Swedish influencers, boosting visibility in the local market.

Outlook and Future Endeavors

Looking ahead, Enzymatica is keen on exploring partnerships beyond Sweden to harness the full commercial potential of ColdZyme. CEO Claus Egstrand indicated an ongoing commitment to enhancing the product’s distribution channels while seeking new markets that can leverage its benefits. The next steps involve a continuous examination of potential partnerships across Europe and beyond while ensuring that their strategies align with the growing demand for effective cold treatments.

Conclusion

Enzymatica's positive revenue trend in Q2 2025, despite its operating losses, reflects a diversified approach towards international expansion and product partnerships. Their focus on ColdZyme indicates a confident transition to broader markets, setting the stage for sustained growth amid evolving global health needs. Further updates on their strategic initiatives and financial performance will be closely watched in the upcoming quarters.